Ypsomed & Adval in mold-making deal:
This article was originally published in Clinica
Executive Summary
Burgdorf-based Ypsomed has agreed to use the injection molding technology of fellow Swiss company Adval Tech Holding in the production of its injection pen and pen needle range. Ypsomed CEO Richard Fritschi said his company could reduce lead times and better standardise the product range by incorporating the Niederwangen company's expertise. Subassembly and components company Adval has been targeting penetration of selected new markets, including medtech and pharma. Its CEO, Jean-Claude Philipona, said the deal would result in added value throughout the entire value chain.
You may also be interested in...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.